4.6 Review

IMMUNITY, HYPOXIA, AND METABOLISM-THE MENAGE A TROIS OF CANCER: IMPLICATIONS FOR IMMUNOTHERAPY

Journal

PHYSIOLOGICAL REVIEWS
Volume 100, Issue 1, Pages 1-102

Publisher

AMER PHYSIOLOGICAL SOC
DOI: 10.1152/physrev.00018.2019

Keywords

cancer; hypoxia; immunometabolism; immunotherapy; metabolism

Categories

Funding

  1. European Research Council (ERC) [773208]
  2. Fonds Wetenschappelijk Onderzoek (Flemish Research Foundation) [G0D1717N, G066515N, 1108919N]
  3. Stichting Tegen Kanker (Fondation Contre le Cancer) [2014197]
  4. Foundation for Science and Technology (FCT) [SFRH/BPD/117858/2016]
  5. Northern Portugal Regional Operational Programme (NORTE 2020) under the Portugal Partnership Agreement, through the European Regional Development Fund (FEDER) [NORTE-01-0145-FEDER-000013]
  6. Northern Portugal Regional Operational Programme (NORTE 2020) under the Portugal Partnership Agreement, through Competitiveness Factors Operational Programme (COMPETE) [NORTE-01-0145-FEDER-000013]
  7. FCT [POCI-01-0145-FEDER-007038]
  8. Swiss National Fund [179235]
  9. Swiss Cancer Research [KFS-4397-02-2018]
  10. National Center of Compentence in Research (NCCR): Kidney Control of Homeostasis [183774]
  11. SNSF [31003A_182470]
  12. ERC [802773-Mito-Guide]
  13. [NORTE-01-0145-FEDER-031142]
  14. [UTAP-EXPL/NTec/0038/2017]
  15. Fundação para a Ciência e a Tecnologia [UTAP-EXPL/NTec/0038/2017] Funding Source: FCT

Ask authors/readers for more resources

It is generally accepted that metabolism is able to shape the immune response. Only recently we are gaining awareness that the metabolic crosstalk between different tumor compartments strongly contributes to the harsh tumor microenvironment (TME) and ultimately impairs immune cell fitness and effector functions. The major aims of this review are to provide an overview on the immune system in cancer; to position oxygen shortage and metabolic competition as the ground of a restrictive TME and as important players in the anti-tumor immune response; to define how immunotherapies affect hypoxia/oxygen delivery and the metabolic landscape of the tumor; and vice versa, how oxygen and metabolites within the TME impinge on the success of immunotherapies. By analyzing preclinical and clinical endeavors, we will discuss how a metabolic characterization of the TME can identify novel targets and signatures that could be exploited in combination with standard immunotherapies and can help to predict the benefit of new and traditional immunotherapeutic drugs.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available